But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 

Archives

Should we prescribe novel anticoagulants or warfarin as first line agents for stroke prevention in AF? video

Recent PE thrombolysis trials: MAPPET, MOPETT, and MUPPET, with Dr Stavros Konstantinides video

The US Postal Service promotes heart health video

Thrombolysis in acute pulmonary embolism: An update with Dr Stavros Konstantinides video

Einstein PE: Rivaroxaban shines as viable monotherapy for pulmonary embolism video

Methods to improve medication adherence video

Henrietta Lacks and the HeLa cell (or how to profit from someone else's cancer cells) video

Reducing risk of VTE with emotional well-being video

INR testing in stable patients: Time to decrease frequency? video

CHEST/ACCP 2012 guidelines: What's new? video

RACE-2: Relaxing rate control in patients with permanent AF video

Preventing postthrombotic syndrome: CAVENT supports the "open vein hypothesis" video

IVC filters: The genie's out of the bottle video

Emergency hospitalization from adverse drug events: Warfarin the biggest culprit video

Self-monitoring INR and self-managing warfarin to reduce thromboembolic events video

Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA